UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mouse Model of Combination Targeted Therapy in PTPN11 Driven Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.10687-10688

2022

Volltextzugriff (PDF)

Hydroxyurea Dosing in Very Young Children (HUGKISS): Challenges of Study Design

Blood, 2022-11, Vol.140 (Supplement 1), p.11108-11109

2022

Volltextzugriff (PDF)

Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)

Blood, 2022-11, Vol.140 (Supplement 1), p.445-446

2022

Volltextzugriff (PDF)

Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer

Blood, 2021-11, Vol.138 (Supplement 1), p.406-406

2021

Volltextzugriff (PDF)

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.6494-6495

2022

Volltextzugriff (PDF)

Education and Promotion of MRD Testing within the Multidisciplinary Cancer Care Team for Adults with Acute Lymphoblastic Leukemia in the Community Setting

Blood, 2019-11, Vol.134 (Supplement_1), p.5834-5834

2019

Volltextzugriff (PDF)

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Blood, 2019-11, Vol.134 (Supplement_1), p.1933-1933

2019

Volltextzugriff (PDF)

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

Blood, 2020-11, Vol.136 (Supplement 1), p.57-58

2020

Volltextzugriff (PDF)

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

Blood, 2020-11, Vol.136 (Supplement 1), p.10-11

2020

Volltextzugriff (PDF)

Mechanism of Escape from LNK Negative Regulation: Constitutively Active JAK2V617F Retains Lysine63-Ubiquitin

Blood, 2017-12, Vol.130, p.2931-2931

2017

Volltextzugriff (PDF)

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

Blood, 2021-11, Vol.138 (Supplement 1), p.407-407

2021

Volltextzugriff (PDF)

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Blood, 2018-11, Vol.132 (Supplement 1), p.730-730

2018

Volltextzugriff (PDF)

Tissue-Resident TSP1-CD47 Signaling Promotes Sickle Cell-Associated Arterial Vasculopathy and Pulmonary Hypertension

Blood, 2017-12, Vol.130 (Suppl_1), p.957-957

2017

Volltextzugriff (PDF)

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Blood, 2017-12, Vol.130, p.431-431

2017

Volltextzugriff (PDF)

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Blood, 2017-12, Vol.130, p.1748-1748

2017

Volltextzugriff (PDF)

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Blood, 2017-12, Vol.130, p.432-432

2017

Volltextzugriff (PDF)

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Blood, 2017-12, Vol.130, p.5345-5345

2017

Volltextzugriff (PDF)

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.693-693

2018

Volltextzugriff (PDF)

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

Blood, 2016-12, Vol.128 (22), p.4385-4385

2016

Volltextzugriff (PDF)

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

Blood, 2017-12, Vol.130 (Suppl_1), p.830-830

2017

Volltextzugriff (PDF)

Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia

Blood, 2018-11, Vol.132 (Supplement 1), p.755-755

2018

Volltextzugriff (PDF)

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Blood, 2016-12, Vol.128 (22), p.5598-5598

2016

Volltextzugriff (PDF)

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

Blood, 2016-12, Vol.128 (22), p.1225-1225

2016

Volltextzugriff (PDF)

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Blood, 2016-12, Vol.128 (22), p.4388-4388

2016

Volltextzugriff (PDF)

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Blood, 2017-12, Vol.130 (Suppl_1), p.656-656

2017

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

ThemaLife Sciences & Biomedicine

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

Mouse Model of Combination Targeted Therapy in PTPN11 Driven Leukemia

Hydroxyurea Dosing in Very Young Children (HUGKISS): Challenges of Study Design

Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)

Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Education and Promotion of MRD Testing within the Multidisciplinary Cancer Care Team for Adults with Acute Lymphoblastic Leukemia in the Community Setting

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

Mechanism of Escape from LNK Negative Regulation: Constitutively Active JAK2V617F Retains Lysine63-Ubiquitin

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Tissue-Resident TSP1-CD47 Signaling Promotes Sickle Cell-Associated Arterial Vasculopathy and Pulmonary Hypertension

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Aktive Filter

Suchergebnisse filtern